• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Press release

SyntheticMR AB: New Multicenter Study Demonstrates SyMRI's Potential to Transform Clinical Neuroimaging Workflows

SyntheticMR

SyntheticMR AB (publ) is proud to share the results of a newly published multicenter clinical study in the American Journal of Neuroradiology (AJNR), demonstrating the diagnostic equivalence-and potential advantages-of SyMRI® using the 3D-QALAS method compared to conventional 3D MRI in routine clinical neuroimaging. 

The peer-reviewed study, available here, evaluated a large and diverse patient population across multiple imaging centers. The findings confirmed that 3D synthetic MRI using SyMRI matched conventional MRI in sensitivity, specificity, and diagnostic accuracy. Notably, SyMRI received even higher ratings for image quality. 

"These results underscore the value of SyMRI in real-world clinical practice," said Johanna Norén, Acting CEO of SyntheticMR. "With diagnostic performance on par with conventional imaging-and with added benefits in workflow efficiency and quantitative imaging-SyMRI has the potential to enhance diagnostic confidence while streamlining MRI protocols." 

The study highlights SyMRI's ability-particularly in 3D-to deliver quantitative, multi-contrast images in a single, fast scan without compromising image quality, making it a strong candidate for advancing scalable and standardized neuroimaging practices. 

This clinical evidence further strengthens SyntheticMR's mission to redefine MRI efficiency, bringing the power of objective, quantitative imaging into routine clinical use.